Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and myotoxicity.

John A Farmer1

  • 1Baylor College of Medicine, One Baylor Plaza, Room 525D, Houston, TX 77030, USA. jfarmer@bcm.tmc.edu

Current Atherosclerosis Reports
|February 8, 2003
PubMed
Summary
This summary is machine-generated.

Statin therapy effectively reduces cardiovascular events but can cause muscle problems like myopathy. Further research is needed to understand the exact mechanisms of statin-associated muscle toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategies for multivessel revascularization in patients with diabetes: the FREEDOM trial.

Current atherosclerosis reports·2014
Same author

The effect of statins on skeletal muscle function: the STOMP trial.

Current atherosclerosis reports·2013
Same author

Aggressive statin therapy and the risk of malignancy.

Current atherosclerosis reports·2013
Same author

Metabolic syndrome in South Asians.

Journal of clinical hypertension (Greenwich, Conn.)·2012
Same author

Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.

Current atherosclerosis reports·2011
Same author

Omega-3 Fatty acids and cardiovascular events after myocardial infarction: the alpha omega trial.

Current atherosclerosis reports·2011

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cardiovascular mortality has declined significantly due to multiple factors.
  • Statin therapy has been crucial in managing dyslipidemia for patients at risk of coronary events.
  • Large-scale trials confirm statin efficacy in reducing cardiovascular morbidity and mortality.

Purpose of the Study:

  • To review the risk-benefit profile of statin therapy, focusing on muscle toxicity.
  • To clarify the relationship between statins and muscle-related adverse effects.
  • To explore potential mechanisms underlying statin-associated muscle toxicity.

Main Methods:

  • Analysis of data from large-scale statin mega-trials.
  • Review of histopathologic studies on statin-induced myopathy.
  • Examination of clinical risk-benefit data regarding reductase inhibitors.

Related Experiment Videos

Main Results:

  • Statin therapy is effective in primary and secondary cardiovascular prevention.
  • Muscle toxicity, including myopathy and myalgias with normal creatine kinase, is an identified risk.
  • Quantitative risk-benefit data from mega-trials have been clarified.

Conclusions:

  • While statins offer significant cardiovascular benefits, muscle toxicity is a recognized clinical risk.
  • The precise mechanisms of statin-associated muscle toxicity are not fully understood.
  • Potential contributing factors include genetic predispositions, drug interactions, metabolic alterations, and intrinsic drug properties.